MedTrace Logo

In-use Tolerance and Efficacy Study Under Dermatological Control of an Anti-aging Cream (Split Face) Post Facial Superficial Rejuvenation Procedures, After re Epidermization

NCT06942403 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-04-24

No results posted yet for this study

Summary

The aim of this study is to assess the dermatological tolerance of the investigational product "Crème visage Product code: RV4983A / Formula code: LA3365" after 95 days for subjects post peeling and LASER and 176 days for subjects post injections of once daily use at the evening on the half face, under normal conditions of use, on 66 subjects.

This study will be conducted as a national, monocentric, open trial.

Planning of the visits:

* Visit 1: Inclusion (Day 1) - The subjects undergo their procedure (peeling, LASER or injections).
* Home application of the associated product 1 period: Day 1 to Day 7
* Visit 2: intermediate visit (Day 8) subjects received investigational product and associated product 2;
* Visit 3, 4, and 5: Intermediate visit (Day 37, Day 66 and Day 95\*),

\*the final visit for the subjects post peeling and LASER
* Visit 6\*\*: End of study (Day 176), \*\* for subjects post injections

Conditions

  • Healthy

Interventions

OTHER

Associated product 1 : RV2666C

Applied twice a day minimum during 7 days (from Day 1 to Day 7)

OTHER

Associated product 2 MORNING : RV5000A

Applied in the mornings from Day 8 to Day 95 or Day 176\* \* for subjects post injections

OTHER

Test product : RV4983A

Applied once a day, at the evening. Avoid contact with eyes. If sensations of discomfort appear, allow more time between applications. * From Day 8 to Day 95 (87 days) for post LASER and post peeling subjects * From Day 8 to Day 176 (169 days) for post-injections subjects

OTHER

Associated product 2 EVENING: RV5000A

Applied in the evenings from Day 8 to Day 95 or Day 176\* \* for subjects post injections

Sponsors & Collaborators

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2024-03-26
Completion
2024-03-26

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06942403 on ClinicalTrials.gov